Cargando…
Cross-laboratory validation of the OncoScan® FFPE Assay, a multiplex tool for whole genome tumour profiling
BACKGROUND: Adoption of new technology in both basic research and clinical settings requires rigorous validation of analytical performance. The OncoScan® FFPE Assay is a multiplexing tool that offers genome-wide copy number and loss of heterozygosity detection, as well as identification of frequentl...
Autores principales: | Foster, Joseph M, Oumie, Assa, Togneri, Fiona S, Vasques, Fabiana Ramos, Hau, Debra, Taylor, Morag, Tinkler-Hundal, Emma, Southward, Katie, Medlow, Paul, McGreeghan-Crosby, Keith, Halfpenny, Iris, McMullan, Dominic J, Quirke, Phil, Keating, Katherine E, Griffiths, Mike, Spink, Karen G, Brew, Fiona |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342810/ https://www.ncbi.nlm.nih.gov/pubmed/25889064 http://dx.doi.org/10.1186/s12920-015-0079-z |
Ejemplares similares
-
Comparing mutation calls in fixed tumour samples between the affymetrix OncoScan® array and PCR based next-generation sequencing
por: Wood, Henry M., et al.
Publicado: (2017) -
Prediction of early-stage hepatocellular carcinoma using OncoScan chromosomal copy number aberration data
por: Yu, Ming-Chin, et al.
Publicado: (2017) -
Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA
por: Togneri, Fiona S, et al.
Publicado: (2016) -
Detection of cytogenomic abnormalities by OncoScan microarray assay for products of conception from formalin-fixed paraffin-embedded and fresh fetal tissues
por: Wen, Jiadi, et al.
Publicado: (2021) -
HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials
por: Richman, Susan D, et al.
Publicado: (2016)